Discrimination between Normal Wildtype and Carriers of Coagulation Factor V Leiden Mutation by the Activated Protein C Resistance Test in the Presence of Factor V Deficient Plasma

Clinical Chemistry and Laboratory Medicine

Volumn 35, Issue 1, 1997, Pages 41-46

  Reuner, Karl H ^a   Litfin, Frank ^a   Patscheke, Heinrich ^a  

^a Klinikum Karlsruhe GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOPHILIA;

BASE SEQUENCE; BLOOD COAGULATION TESTS; DNA PRIMERS; FACTOR V; FACTOR V DEFICIENCY; FEMALE; GENOTYPE; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTEIN C; REFERENCE VALUES; THROMBOPHLEBITIS;

EID: 0031051324     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.1997.35.1.41     Document Type: Article

References (25)

1. Dahlbäck B. Resistance to activated protein C., the Arg506 to Gin mutation in the factor V gene, and venous thrombosis. Thromb Haemost 1995; 73:739-742.
2. Kirschbaum N. E., Foster P. A., The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance. Thromb Haemost 1995; 74:874-878.
3. Rees D. C., Cox M., Clegg J. B., World distribution of factor V Leiden. Lancet 1995; 346:1133-1134.
4. Bertina R. M., Koeleman BPC, Koster T., Rosendaal F. R., Dirven R. J., de Ronde H.,et al., Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-7.
5. van Boven H. H., Reitsma P. H., Rosendaal F. R., Bayston T. A., Chowdhury V., Bauer K. A., et al., Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75:417-421.
6. Kalafatis M., Lu D., Bertina R. M., Long G. L., Mann K. G., Biochemical prototype for familial thrombosis. A study combining a functional protein C mutation and factor V Leiden. Arterioscler Thromb Vase Biol 1995; 15:2181-2187.
7. Koeleman BPC, van Rumpt D., Hamulyak K., Reitsma P. H., Bertina R. M., Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995; 74:580-583.
8. Zöller B., Bemtsdotter A., Garcia de Frutos P., Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85:3518-3523.
9. Vandenbroucke J. P., Koster T., Briet E., Reitsma P. H., Bertina R. M., Rosendaal F. R., Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344:1453-1457.
10. Bridey F., Wolff M., Laissy J. P., Morin V., Lefebvre M., de Prost D. Fatal cerebral venous sinus thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives. Thromb Haemost 1995; 74:1382.
11. Rosendaal F. R., Oral contraceptives and screening for factor V Leiden. Thromb Haemost 1996; 75:524-525.
12. Dahlbäck B., Carlsson M., Svensson P. J., Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sei USA 1993; 90:1004-1008.
13. de Ronde H., Bertina R. M., Laboratory diagnosis of APC resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72:880-886.
14. Hassett C., Faruki H., Bontempo F. A., An evaluation of APC resistance and factor V Leiden in an unselected patient population. Blood 1995; 86:915a.
15. Jorquera B., Montoro J. M., Fernandez M. A., Aznar J. A., Aznar J. Modified test for activated protein C resistance. Lancet 1994, 344:1162-1163.
16. Trossaert M., Conard J., Horrellou M. H., Samama M. M., Ireland H., Bayston T. A.,et al., Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344:1709.
17. Engel H., Zwang L., Van Vliet H. H., Michiels J. J., Stibbe J., Lindemans J. Phenotyping and genotyping of coagulation factor V Leiden. Thromb Haemost 1996; 75:267-269.
18. Gouault-Heilmann M., Leroy-Matheron C. Factor V Leidendependent APC resistance: improved sensitivity and specificity of the APC resistance test by plasma dilution in factor V-depleted plasma. Thromb Res 1996; 82:281-283.
19. Cadroy Y., Sie P., Alhenc-Gelas M., Aiach M. Evaluation of APC resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants. Thromb Haemost 1995; 73:734-735.
20. Trossaert M., Conard J., Horellou M. H., Elalamy I., Samama, MM. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemost 1996; 75:521-522.
21. Leroy-Matheron C., Levent M., Pignon J. M., Mendonca C., Gouault-Heilmann M. The 1691 G-A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Thromb Haemost 1996; 75:4-10.
22. Zehnder J. L., Benson R. C., Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden. Am J Clin Pathol 1996; 106:107-111.
23. Bellissimo D. B., Kirschbaum N. E., Foster P. A., Improved method for factor V Leiden typing by PCR-SSP. Thromb Haemost 1996; 75:520.
24. Rintelen C., Pabinger I., Knoebl P., Lechner K., Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996; 75:229-232.
25. Kraus M., Zander N., Fickenscher K. Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C. Thromb Res 1995; 80:255-264.